Glycine-β-muricholic Acid

目录号: GC40911纯度: >98.00%同义词: Gly-MCA, GβMCA
Glycine-β-muricholic Acid是一种有效的、稳定的、对精氨酸有选择性的口服生物活性FXR抑制剂,是鼠特异性初级胆汁酸β-鼠胆酸的甘氨酸结合形式。

Glycine-β-muricholic Acid
Cas No.: 66225-78-3
规格价格库存数量操作
5mg¥3,375.00现货
1
10mg¥5,400.00现货
1
10mM (in 1mL DMSO)¥3,457.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Glycine-β-muricholic Acid is an effective, stable, and arginine-selective oral bioactive FXR inhibitor. It is the glycine-bound form of the murine primary bile acid β-muricholic acid. FXR is an important sensor and regulator of bile acid, lipid, and glucose metabolism [1]. Glycine-β-muricholic Acid can be used in studies of metabolic disorders [2].

In vivo, Glycine-β-muricholic Acid (10 and 50mg/kg; 5 weeks; oral) significantly reduced the absolute fat mass and fat-to-weight ratio of obese and insulin-resistant mice induced by HFD, as well as insulin resistance and hepatic steatosis, with a significant decrease in liver lipid droplets [1]. Glycine-β-muricholic Acid (10mg/kg/day; 23d once every 2 days; Gavage) treatment significantly reduced the protective effect of Lactobacillus reuteri on alcohol-induced lipid accumulation in the liver of mice. Lactobacillus reuteri and its metabolites may regulate liver inflammation through the FXR signaling regulatory axis [3].

References:
[1] Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
[2] Hasan M N, Wang H, Luo W, et al. Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice[J]. Journal of Lipid Research, 2024, 65(10). 
[3] Cheng Y, Xiang X, Liu C, et al. Transcriptomic analysis reveals Lactobacillus reuteri alleviating alcohol-induced liver injury in mice by enhancing the farnesoid X receptor signaling pathway[J]. Journal of agricultural and food chemistry, 2022, 70(39): 12550-12564.

Glycine-β-muricholic Acid是一种有效的、稳定的、对精氨酸有选择性的口服生物活性FXR抑制剂,是鼠特异性初级胆汁酸β-鼠胆酸的甘氨酸结合形式。FXR是胆汁酸、脂质和葡萄糖代谢的重要传感器和调节因子 [1]。Glycine-β-muricholic Acid可用于代谢障碍的研究 [2]

在体内,Glycine-β-muricholic Acid(10和50mg/kg; 5 weeks; oral)显著降低了HFD诱导的肥胖和胰岛素抵抗小鼠的绝对脂肪质量和脂肪/瘦体重比,以及胰岛素抵抗和肝脂肪变性,肝脏脂滴显著减少 [1]。Glycine-β-muricholic Acid(10mg/kg/day; 23d once every 2 days; gavage)显著降低了Lactobacillus reuteri对酒精诱导的小鼠肝脏脂质蓄积的保护作用,Lactobacillus reuteri及其代谢产物可能通过FXR信号调节轴调节肝脏炎症 [3]

实验参考方法 Experimental Reference Method

Animal experiment [1]:

Animal models

C57BL/6N mice

Preparation Method

For thermal neutral temperature exposure experiments, male 6-week-old C57BL/6N mice fed a HFD were orally administered with vehicle (control pills) or Glycine-β-muricholic Acid (0.25mg per pill per day, dose10mg kg−1) at 29.5°C for 2 weeks. For cold stimulation experiments, male 6-week-old C57BL/6N mice fed a HFD were orally administered with vehicle (control pills) or Glycine-β-muricholic Acid (0.25mg per pill per day, dose 10mg kg−1) at 22°C for 5 days and then acutely moved to 5°C for another 1 day. All mice were randomly assigned to experimental groups and the groups showed no difference in body weight gain before treatment.

Dosage form

10mg/kg/day for 5 days and two weeks; p.o.

Applications

A short-duration 5-day treatment with Glycine-β-muricholic Acid specifically increases beige fat thermogenesis and energy expenditure before body weight change.

References:
[1] Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).

产品文档 Product Documents

Purity:>98.00%

化学性质Chemical Properties

CAS 号
66225-78-3
同义词
Gly-MCA, GβMCA
化学名
N-[(3α,5β,6β,7β)-3,6,7-trihydroxy-24-oxocholan-24-yl]-glycine
SMILES
O[C@@H]1CC[C@@]2(C)[C@@]([C@H](O)[C@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCC(O)=O)=O)([H])C1
分子式
C26H43NO6
分子量
465.6 g/mol
溶解性
20mg/mL in ethanol, or in DMSO, 20mg/mL in DMF
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol